MA50654A - Anticorps anti-pacap - Google Patents

Anticorps anti-pacap

Info

Publication number: MA50654A
Authority: MA; Morocco
Prior art keywords: pacap antibodies; pacap; antibodies
Prior art date: 2017-09-29

Application number

MA050654A

Other languages

English (en)

Inventor

Catherine Brautigam Beidler

Michael Parvin Johnson

Chetankumar Natvarlal Patel

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-29

Filing date

2018-09-20

Publication date

2020-08-05

2018-09-20 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-08-05 Publication of MA50654A publication Critical patent/MA50654A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA050654A 2017-09-29 2018-09-20 Anticorps anti-pacap MA50654A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762565278P	2017-09-29	2017-09-29

Publications (1)

Publication Number	Publication Date
MA50654A true MA50654A (fr)	2020-08-05

Family

ID=63794713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050654A MA50654A (fr)	2017-09-29	2018-09-20	Anticorps anti-pacap

Country Status (27)

Country	Link
US (3)	US10519225B2 (fr)
EP (1)	EP3688035A1 (fr)
JP (2)	JP6952888B2 (fr)
KR (1)	KR102453573B1 (fr)
CN (1)	CN111164105B (fr)
AR (1)	AR113022A1 (fr)
AU (1)	AU2018341959B2 (fr)
BR (1)	BR112020003628A2 (fr)
CA (1)	CA3077304C (fr)
CL (1)	CL2020000705A1 (fr)
CO (1)	CO2020002170A2 (fr)
CR (1)	CR20200127A (fr)
DO (1)	DOP2020000060A (fr)
EA (1)	EA202090563A1 (fr)
EC (1)	ECSP20020293A (fr)
IL (1)	IL273529A (fr)
JO (1)	JOP20200069A1 (fr)
MA (1)	MA50654A (fr)
MX (1)	MX2020003563A (fr)
MY (1)	MY199876A (fr)
NZ (1)	NZ762312A (fr)
PE (1)	PE20201494A1 (fr)
PH (1)	PH12020550340A1 (fr)
SG (1)	SG11202002572YA (fr)
TW (1)	TWI701260B (fr)
WO (1)	WO2019067293A1 (fr)
ZA (1)	ZA202001058B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2017013113A (es)	2015-04-16	2018-07-06	Alder Biopharmaceuticals Inc	Anticuerpos anti-pacap y sus usos.
CA3020839A1 (fr) *	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Anticorps anti-pacap et leurs utilisations
EP4045641A1 (fr)	2019-10-15	2022-08-24	Eli Lilly and Company	Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison
IL310329A (en) *	2021-07-29	2024-03-01	Cephalon Llc	Preparations and methods for anti-PACAP antibodies
TW202330607A (zh) *	2021-09-30	2023-08-01	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合ｃｇｒｐ和ｐａｃａｐ的抗原結合分子及其醫藥用途
KR102839881B1 (ko) *	2021-11-19	2025-07-31	대한민국	방송통신기자재 성능 측정 시스템 및 그 방법
WO2024218541A1 (fr) *	2023-04-20	2024-10-24	Mark Hasleton	Traitement de la migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3107225B2 (ja) *	1990-03-17	2000-11-06	武田薬品工業株式会社	Ｐａｃａｐに対する抗体およびその用途
US6037321A (en)	1995-05-03	2000-03-14	Biostar Inc.	Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr)	2001-07-02	2005-02-25	Gemplus Card Int	Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
EP1583550A2 (fr)	2003-01-16	2005-10-12	D. Collen Research Foundation vzw	Inhibition de la signalisation pacap dans la prevention et le traitement de la thrombocytopenie
WO2012106407A2 (fr)	2011-02-01	2012-08-09	The University Of Vermont And State Agricultural College	Procédés diagnostiques et thérapeutiques et produits liés aux troubles de l'anxiété
JP6064861B2 (ja)	2013-03-05	2017-01-25	株式会社デンソー	熱電変換装置の製造方法
TWI636064B (zh) *	2013-03-15	2018-09-21	安美基公司	人類ｐａｃ１抗體
EP3035950A4 (fr)	2013-08-14	2017-05-03	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Analogues de pacap/vip glycosylés avec pénétration du snc augmentée pour le traitement de maladies neurodégénératives
MX2017013113A (es)	2015-04-16	2018-07-06	Alder Biopharmaceuticals Inc	Anticuerpos anti-pacap y sus usos.
US10822408B2 (en) *	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
WO2017142961A1 (fr)	2016-02-16	2017-08-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Traitement de lésion cérébrale traumatique ou d'accident vasculaire cérébral

2018
- 2018-09-13 AR ARP180102618A patent/AR113022A1/es not_active Application Discontinuation
- 2018-09-14 TW TW107132467A patent/TWI701260B/zh active
- 2018-09-20 BR BR112020003628-5A patent/BR112020003628A2/pt not_active Application Discontinuation
- 2018-09-20 JP JP2020517489A patent/JP6952888B2/ja active Active
- 2018-09-20 AU AU2018341959A patent/AU2018341959B2/en not_active Ceased
- 2018-09-20 NZ NZ762312A patent/NZ762312A/en not_active IP Right Cessation
- 2018-09-20 PH PH1/2020/550340A patent/PH12020550340A1/en unknown
- 2018-09-20 SG SG11202002572YA patent/SG11202002572YA/en unknown
- 2018-09-20 MA MA050654A patent/MA50654A/fr unknown
- 2018-09-20 JO JOP/2020/0069A patent/JOP20200069A1/ar unknown
- 2018-09-20 PE PE2020000375A patent/PE20201494A1/es unknown
- 2018-09-20 CR CR20200127A patent/CR20200127A/es unknown
- 2018-09-20 MX MX2020003563A patent/MX2020003563A/es unknown
- 2018-09-20 EP EP18783282.9A patent/EP3688035A1/fr active Pending
- 2018-09-20 KR KR1020207008789A patent/KR102453573B1/ko active Active
- 2018-09-20 CA CA3077304A patent/CA3077304C/fr active Active
- 2018-09-20 CN CN201880063106.2A patent/CN111164105B/zh active Active
- 2018-09-20 MY MYPI2020001596A patent/MY199876A/en unknown
- 2018-09-20 US US16/136,490 patent/US10519225B2/en active Active
- 2018-09-20 WO PCT/US2018/051898 patent/WO2019067293A1/fr not_active Ceased
- 2018-09-20 EA EA202090563A patent/EA202090563A1/ru unknown
2019
- 2019-11-22 US US16/692,236 patent/US10954292B2/en active Active
2020
- 2020-02-19 ZA ZA2020/01058A patent/ZA202001058B/en unknown
- 2020-02-27 CO CONC2020/0002170A patent/CO2020002170A2/es unknown
- 2020-03-16 DO DO2020000060A patent/DOP2020000060A/es unknown
- 2020-03-18 CL CL2020000705A patent/CL2020000705A1/es unknown
- 2020-03-23 IL IL273529A patent/IL273529A/en unknown
- 2020-03-26 EC ECSENADI202020293A patent/ECSP20020293A/es unknown
2021
- 2021-02-15 US US17/175,870 patent/US20210171616A1/en not_active Abandoned
- 2021-09-28 JP JP2021157701A patent/JP7221352B2/ja active Active

Also Published As

Publication number	Publication date
PE20201494A1 (es)	2020-12-29
JP2020535167A (ja)	2020-12-03
JP7221352B2 (ja)	2023-02-13
SG11202002572YA (en)	2020-04-29
TW201920280A (zh)	2019-06-01
NZ762312A (en)	2022-11-25
CL2020000705A1 (es)	2020-09-11
WO2019067293A1 (fr)	2019-04-04
AR113022A1 (es)	2020-01-15
JOP20200069A1 (ar)	2020-04-28
EA202090563A1 (ru)	2020-06-24
MX2020003563A (es)	2020-08-03
CO2020002170A2 (es)	2020-04-01
TWI701260B (zh)	2020-08-11
PH12020550340A1 (en)	2022-05-02
CN111164105B (zh)	2023-07-04
BR112020003628A2 (pt)	2020-09-01
US20200131256A1 (en)	2020-04-30
DOP2020000060A (es)	2020-08-15
CN111164105A (zh)	2020-05-15
CA3077304C (fr)	2023-08-01
ZA202001058B (en)	2022-06-29
ECSP20020293A (es)	2020-06-30
CR20200127A (es)	2020-04-08
AU2018341959B2 (en)	2021-11-25
JP2022000049A (ja)	2022-01-04
KR102453573B1 (ko)	2022-10-12
US10954292B2 (en)	2021-03-23
EP3688035A1 (fr)	2020-08-05
AU2018341959A1 (en)	2020-03-05
CA3077304A1 (fr)	2019-04-04
IL273529A (en)	2020-05-31
US20210171616A1 (en)	2021-06-10
US20190100579A1 (en)	2019-04-04
KR20200040881A (ko)	2020-04-20
MY199876A (en)	2023-11-27
US10519225B2 (en)	2019-12-31
JP6952888B2 (ja)	2021-10-27

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
IL272227A (en)	2020-03-31	Anti-tigit antibodies
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
IL269405A (en)	2019-11-28	Anti-sirp alpha antibodies
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3661558A4 (fr)	2021-08-11	Anticorps anti-il1rap
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
MA46057A (fr)	2019-07-03	Anticorps anti-ctla4
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
EP3691447A4 (fr)	2021-08-11	Anticorps anti-transthyrétine
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine